Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05836883 · ClinicalTrials.gov registry record · Phase 1
Study of ExoFlo for the Treatment of Perianal Fistulas
A Phase 1 study, sponsored by Direct Biologics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05836883 is a Phase 1 study that was terminated before completion, run by Direct Biologics. The registered enrollment target is 5 participants.
The verdict
NCT05836883, a Phase 1 study, was terminated before completion, sponsored by Direct Biologics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
To evaluate the safety and feasibility of ExoFlo as a treatment for Perianal Fistulizing Crohn's Disease.
Interventions
- BIOLOGICAL ExoFlo
- OTHER Local injection of normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-08-28 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05836883
The ClinicalTrials.gov registry entry for NCT05836883 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Direct Biologics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ExoFlo is the first listed.
NCT05836883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05836883 about?
NCT05836883 is a clinical study titled "Study of ExoFlo for the Treatment of Perianal Fistulas". To evaluate the safety and feasibility of ExoFlo as a treatment for Perianal Fistulizing Crohn's Disease.
What is the current status of trial NCT05836883?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2023-08-28. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT05836883?
The interventions under investigation include: ExoFlo (BIOLOGICAL), Local injection of normal saline (OTHER).
Who is sponsoring clinical trial NCT05836883?
This trial is sponsored by Direct Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.